We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Mac-2 binding protein glycosylation isomer, the FIB-4 index, and a combination of the two as predictors of non-alcoholic steatohepatitis.
- Authors
Kiyoaki, Ito; Sumida, Yoshio; Nakade, Yukiomi; Okumura, Akinori; Nishimura, Sayaka; Ibusuki, Mayu; Kitano, Rena; Sakamoto, Kazumasa; Kimoto, Satoshi; Inoue, Tadahisa; Kobayashi, Yuji; Fukuzawa, Yoshitaka; Yoneda, Masashi
- Abstract
Approximately 10% non-alcoholic fatty liver disease (NAFLD) cases progress to non-alcoholic steatohepatitis (NASH). Liver biopsy, the gold standard for diagnosing NASH and associated liver fibrosis, is invasive with a risk of life-threatening complications. Therefore, reliable non-invasive biomarkers for predicting NASH are required to prevent unnecessary liver biopsies. We evaluated the performance of two non-invasive fibrosis markers, Mac-2 binding protein glycosylation isomer (M2BPGi) and the FIB-4 index for predicting the fibrosis staging, NAFLD activity scoring (NAS) index, and NASH. We also analyzed the correlation between the two markers. The sensitivities, specificities, positive predictive values (PPV), and negative predictive values of the FIB-4 index, M2BPGi, and a combination of both markers for NASH diagnosis were evaluated. The M2BPGi and FIB-4 index showed a good performance in diagnosing NASH, the fibrosis stage, and the NAS index in NAFLD patients. While both markers were well-correlated with each other in most cases, no correlation was found in some patients. Compared with the FIB-4 index or the M2BPGi alone, a combination of the two showed a higher specificity, PPV, and accuracy for NASH diagnosis. The M2BPGi and the FIB-4 index are easily accessible and reliable liver fibrosis markers. Diseases other than liver disease may cause dissociation between the two markers, causing failure to predict NASH. However, the combination of both markers can compensate for their disadvantages. Because the PPV of the combination was relatively high, patients who test positive for both markers should undergo liver biopsy for NASH diagnosis.
- Subjects
NATIONAL Academy of Sciences (U.S.); NON-alcoholic fatty liver disease; CARRIER proteins; HEPATIC fibrosis; GLYCOSYLATION; ISOMERS; LIVER biopsy
- Publication
PLoS ONE, 2022, Vol 17, Issue 11, p1
- ISSN
1932-6203
- Publication type
Article
- DOI
10.1371/journal.pone.0277380